Rajeev Khanna, MD
Internal Medicine · Sterling, VANPI 1609886712
Payments from drug & device makers
Across 377 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Davol Inc.$1K
- AbbVie$913
- Amgen$477
- Lilly USA, LLC$420
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$1,00011%
- Food & beverage$7,77188%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 125 | $2,088 |
| AstraZeneca | 82 | $1,808 |
| Davol Inc. | 1 | $1,000 |
| AbbVie(2 entities) | 34 | $913 |
| Amgen | 23 | $477 |
| Lilly USA, LLC | 22 | $420 |
| Teva Pharmaceuticals USA, Inc. | 2 | $229 |
| Pfizer | 7 | $203 |
| Johnson & Johnson | 9 | $183 |
| Esperion Therapeutics, Inc. | 4 | $174 |
| Novartis | 9 | $157 |
| Astellas Pharma US Inc | 3 | $128 |
| Boehringer Ingelheim | 5 | $111 |
| Dexcom, Inc. | 4 | $108 |
| Phathom Pharmaceuticals, Inc. | 6 | $106 |
| Bayer | 6 | $104 |
| Amarin Pharma, Inc. | 5 | $94 |
| Genentech USA, Inc. | 5 | $93 |
| Merck | 5 | $84 |
| Shire North American Group Inc | 1 | $54 |
| Endo Pharmaceuticals Inc. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Medtronic | 1 | $26 |
| Mylan Specialty L.p. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Vistapharm, Inc. | 1 | $14 |
| Biogen | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,877 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 81 | $108,451 |
| OzempicSemaglutide | 47 | $97,502 |
| JardianceEmpagliflozin | 61 | $97,330 |
| MounjaroTirzepatide | 27 | $42,968 |
| EliquisApixaban | 31 | $29,367 |
| RybelsusSemaglutide | 17 | $26,441 |
| JanuviaSitagliptin Phosphate | 14 | $22,823 |
| LinzessLinaclotide | 11 | $7,174 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $6,227 |
| Levothyroxine Sodium | 315 | $2,595 |
| Atorvastatin Calcium | 363 | $2,438 |
| Rosuvastatin Calcium | 188 | $1,857 |
| Metformin Hcl | 280 | $1,794 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,660 |
| Amlodipine Besylate | 297 | $1,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,088 | $123,94364 claims |
| AstraZenecaFarxiga | $1,808 | $108,45181 claims |
| Boehringer IngelheimJardiance | $111 | $97,33061 claims |
| Lilly USA, LLCMounjaro | $420 | $42,96827 claims |
| PfizerEliquis | $203 | $29,36731 claims |
| MerckJanuvia | $84 | $22,82314 claims |
| AbbVieLinzess | $913 | $7,17411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,595315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Sterling
- Ravi IyerSterling$38K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.